-transparent.png){kind=logo}
A phase II study study employing 5-fluorouracil, mitomycin C, and streptozotocin in unresectable pancreatic carcinoma was performed. Seven of 22 patients (32%) responded and 4 of 22 (18%) had stable disease. Median survival of the entire group was 6 months, and of responders 9.5 months. In 13 patients with localized disease, five responses (38%) were seen and median survival was 7.5 months. Toxicity of the regimen was moderate, being predominantly gastrointestinal and renal. The usefulness of this regimen in localized pancreatic cancer should be explored further.
Related Publications
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
July 1982,
Cancer,
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
February 1978,
Cancer,
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
January 1998,
Clinical oncology (Royal College of Radiologists (Great Britain)),
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
November 1991,
Clinical oncology (Royal College of Radiologists (Great Britain)),
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
April 1978,
Cancer treatment reports,
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
February 2005,
The oncologist,
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
November 1980,
Cancer,
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
February 1989,
American journal of clinical oncology,
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
October 1984,
American journal of clinical oncology,
R M Bukowski, and
R T Abderhalden, and
J S Hewlett, and
J K Weick, and
C W Groppe
June 1990,
Cancer,
